PerkinElmer (PKI), a leading name in medical technology, recently announced the acquisition of SIRION Biotech GmbH, a provider of viral vector-based technologies. The transaction is likely to close in the third quarter of 2021. The terms of the deal have not been disclosed yet. Following the news, shares of the company rose marginally to close at $153.20 in Tuesday’s trading session. CEO of PerkinElmer Prahlad Singh said, “By combining SIRION’s innovative "payload" transport technology with our existing Horizon genetic material editing tools and phenotypic research solutions, we will be able to support organizations’ cell and gene therapy workflows as they look to streamline and accelerate their efforts.
https://www.tipranks.com/news/perkinelmer-to-acquire-sirion-biotech
PerkinElmer (NYSE:PKI)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more PerkinElmer Charts.
PerkinElmer (NYSE:PKI)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more PerkinElmer Charts.